Time for a Reset: Using Modern Tools and Frameworks to Reengineer Multiple Sclerosis Management

West Palm Beach, FL US
February 28, 2025

A Satellite Symposium held during ACTRIMS Form 2025

This CE activity is provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. This independently supported Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation and is not included in the ACTRIMS Forum 2025 accredited program.

Program Description

It is now recognized that relapsing and progressive multiple sclerosis (MS) form a disease spectrum rather than distinct entities, meaning that progression can begin early in the disease course. This makes the fact that most disease modifying therapies (DMT) lack data or are ineffective in treatment of progression particularly problematic as an agent could improve disease activity but allow disability to accumulate in the background. Thus, the approach to early clinical decisions is paramount and may need to be rethought. Further, many patients report struggling with worsening that lacks explanation, highlighting potential insufficiencies in routine monitoring strategies. While more sensitive tools are being investigated, there are questions regarding which should/can be utilized routinely and how/when they should impact clinical decisions.

This symposium is designed to walk through MS management from the beginning, taking all these novel considerations into account. At each clinical decision point, you will join leading experts in deciding optimal treatment approaches and answering key questions in an evolving space. 

Target Audience

The target audience for this CME initiative includes neurodegenerative disease specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
  • Evaluate the optimal roles of current and emerging biomarker-based (e.g., s-NfL, advanced imaging) assessment tools for monitoring disease activity, progression, and therapeutic response
  • Compare the mechanisms and literature reported outcomes of current and emerging (e.g., Bruton’s tyrosine kinase inhibitors [BTKis]) DMTs with evidence in both disease activity and progression to optimize clinical decision making
  • Identify challenging and impactful clinical symptoms (e.g., cognitive impairment, fatigue) of MS progression and how they influence management to improve shared decision-making (SDM) and patient quality of life (QoL).
Course summary
Course opens: 
12/25/2024
Course expires: 
02/28/2025
Event starts: 
02/28/2025 - 8:00am EST
Event ends: 
02/28/2025 - 9:00am EST
Cost:
$0.00
Add to calendar: 
Rating: 
0

A case presentation will be used to structure the discussion as you would chronologically encounter each issue in your own practice. At each key decision point, both faculty and audience (where applicable) preferences will be displayed followed by short literature-based justification and panel discussion.

Agenda

 

Introduction: Multiple Sclerosis (MS) – An Evolving Entity (3 min)

  • Changing understanding of MS and its influence on expectations, monitoring, and treatment

MODULE 1: Establishing a Baseline: Laying a Foundation for Optimized Monitoring and Decision-Making (17 min)

  • Which metrics to assess at baseline and the role of rising serum and advanced imaging metrics
  • Successes and failures in prognostication; implications for treatment and monitoring

MODULE 2: Applying Modern MS Frameworks to Upfront Clinical Decisions (20 min)

  • Upfront treatment strategies to mitigate disability accumulation and encourage no evidence of disease activity (NEDA)
  • Application of current and emerging treatments in progressive disease
  • Current status of BTKis and their expected clinical roles

MODULE 3: Ongoing Monitoring and Management Considerations (15 min)

  • Tools and strategies for evaluating treatment response
  • Strategies for DMT switching
  • When to act on progression

Q&A (5 min)

Hilton West Palm Beach
600 Okeechobee Boulevard
Level One, Oceana Ballroom AB
West Palm Beach, FL 33401
United States

Parking & Directions

   Stephen Krieger, MD, FAAN (Chair & Moderator)
   Professor of Neurology
   Corinne Goldsmith Dickinson Center for MS
   Icahn School of Medicine at Mount Sinai
   New York, NY

 

   Jaqueline Nicholas, MD, MPH
   System Chief, Neuroimmunology & MS
   Program Director, Neuroimmunology Fellowship
   OhioHealth MS Center
   Columbus, OH

   Enrique Alvarez, MD, PhD
   Professor, Neurology
   University of Colorado School of Medicine
   Aurora, CO

 This CE activity is provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. This independently supported Satellite Symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation and is not included in the ACTRIMS Forum 2025 accredited program.

    

Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

PHYSICIAN CREDIT
Purdue University designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
ADVANCED PRACTICE PROFESSIONALS
The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME. Additionally, the American Academy of Physician Associates (PAs) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from providers accredited by the ACCME. As a result, NPs and PAs are included as a target audience.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the live activity enabling participants to register their credit with the appropriate licensing boards or associations.

Conflicts of Interest Disclosure Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. 
 

Commercial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Price

Cost:
$0.00
Please login or register to take this course.

ACTRIMS Forum 2025 registration is required to attend this independent Industry Supported Satellite Symposium. Register online at forum.actrims.org.